newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into